Xuanzhu Biopharmaceutical Co (HKSE:02575) GF Score: 11/100 (As of Aug. 10, 2026) — 10% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02575 Xuanzhu Biopharmaceutical Co Ltd HKSE:02575
11 GF Score
Price HK$12.88
! 1 Warning Sign
View Full Analysis

What is Xuanzhu Biopharmaceutical Co GF Score?

Xuanzhu Biopharmaceutical Co HKSE:02575 +3.21% 11 GF Score is 11 as of Aug. 10, 2026, which is 10% above its 10-year median of 10.00. GuruFocus rates HKSE:02575 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Xuanzhu Biopharmaceutical Co has the GF Score of 11, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 9/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Xuanzhu Biopharmaceutical Co might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Xuanzhu Biopharmaceutical Co  (HKSE:02575) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Xuanzhu Biopharmaceutical Co GF Score Related Terms

HKSE:02575 vs ZTS: GF Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Xuanzhu Biopharmaceutical Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xuanzhu Biopharmaceutical Co GF Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Xuanzhu Biopharmaceutical Co's GF Score distribution charts can be found below:

* The bar in red indicates where Xuanzhu Biopharmaceutical Co's GF Score falls into.


HKSE:02575
11GF Score
Xuanzhu Biopharmaceutical Co Ltd HKSE:02575
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 11 mean?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a GF Score of 11 as of Aug. 10, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. This is 10% above median its historical median of 10.00. Over the past decade, Xuanzhu Biopharmaceutical Co's GF Score has ranged from 7.00 to 12.00.
Is Xuanzhu Biopharmaceutical Co's GF Score too high?
Xuanzhu Biopharmaceutical Co's current GF Score of 11 is 10% above median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 12.00. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's GF Score compare to ZTS?
Xuanzhu Biopharmaceutical Co's GF Score of 11 can be compared against companies in the Drug Manufacturers industry. Historically, Xuanzhu Biopharmaceutical Co's own GF Score has ranged from 7.00 to 12.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. Xuanzhu Biopharmaceutical Co's current GF Score is 11, which is 10% above median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a current GF Score of 11. The current GF Score is 11, which is 10% above median its 10-year median of 10.00. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (HKSE:02575), the current GF Score is 11 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xuanzhu Biopharmaceutical Co Business Description

Address Zhubang 2000 Business Center, 2107, Building 2, Balizhuang Xili, Chaoyang District, Beijing, CHN
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score

Get the complete analysis for HKSE:02575

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$12.88
Price